| RYLSX | VCDAX | RYLSX / VCDAX | |
| Total Expense Ratio | 1.64 | 0.09 | 1,822% |
| Annual Report Gross Expense Ratio | 1.69 | 0.09 | 1,878% |
| Fund Existence | 22 years | 21 years | - |
| Gain YTD | -2.124 | -0.608 | 349% |
| Front Load | 5% | N/A | - |
| Min. Initial Investment | 2500 | 100000 | 3% |
| Min. Initial Investment IRA | 1000 | N/A | - |
| Net Assets | 6.27M | 6.83B | 0% |
| Annual Yield % from dividends | 0.06 | 0.73 | 9% |
| Returns for 1 year | -2.83 | 5.94 | -48% |
| Returns for 3 years | 23.39 | 35.43 | 66% |
| Returns for 5 years | -2.49 | 24.56 | -10% |
| Returns for 10 years | 58.82 | 215.48 | 27% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| IJPIX | 16.64 | 0.39 | +2.40% |
| VY® JPMorgan Emerging Markets Equity S | |||
| VSNGX | 69.90 | -0.18 | -0.26% |
| JPMorgan Mid Cap Equity I | |||
| JSIGX | 22.57 | -0.13 | -0.57% |
| Jacob Small Cap Growth Institutional | |||
| ETAHX | 53.90 | -0.88 | -1.61% |
| Eventide Healthcare & Life Sciences A | |||
| GLDIX | 41.59 | -1.24 | -2.90% |
| Gabelli Gold I | |||